echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Aurora A Small Molecule Oral Inhibitor Approved for Clinical Trial in China

    Aurora A Small Molecule Oral Inhibitor Approved for Clinical Trial in China

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, VIC-1911, a small molecule oral inhibitor of Aurora A from JSI Indah Pharmaceutical Technology Co.
    , Ltd.
    , received a clinical phase 1 approval issued by the National Medical Products Administration.
    The approved indication is the combination with paclitaxel for the treatment of advanced ovarian cancer, Patients with fallopian tube cancer and primary peritoneal cancer


    VIC-1911 from JSI Inda is a highly selective Aurora A (Aurora Kinase A) small molecule oral inhibitor, which effectively reduces the myelosuppressive toxicity of pan-Aurora kinase inhibitors developed in the early stage
    The drug has completed a phase 1 clinical trial in the United States, and the results show that the compound is well tolerated in humans and has potential anti-cancer activity in multiple tumor types


    At present, patients with advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer do not have very effective treatments other than surgery, radiotherapy and chemotherapy
    Especially for ovarian cancer, there are about 51,000 new patients and 23,000 deaths in China every year, the 5-year survival rate is 46%, and the recurrence rate of advanced ovarian cancer is as high as 85%

    The combination of VIC-1911 and paclitaxel has the potential to prolong patient survival and reduce the recurrence rate


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.